Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,156.35 +28.56 (+0.56%) Dow
38,721.13 +45.45 (+0.12%) Nasdaq
16,265.57 +109.24 (+0.68%) Bitcoin USD
63,388.56 -977.18 (-1.52%) CMC Crypto 200
1,361.73 +49.10 (+3.74%)
BCRX Jan 2025 25.000 put
- GuruFocus.com
BioCryst Pharmaceuticals Reports Strong Q1 2024 Results, Exceeding Analyst Revenue Forecasts
Significant Growth in ORLADEYO Sales and Strategic Pipeline Advancements Mark the Quarter
- Zacks
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of 26.09% and 8.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million— —Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) — —Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials— RESEARCH TRIANGLE PARK, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2024, and pr
